4th Quarter - Report
SPARK THERAPEUTICS, INC. for SPARK THERAPEUTICS, INC.
Client
Income
—
Expenses
$160,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues relating to gene therapy; Issues relating to the need for value-based payment arrangements; S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEREMY ALLEN | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| ROCHE HOLDINGS, LTD. | Switzerland | Switzerland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.